Our insights into determinants of peptide abundance changes with IFNγ exposure could be useful to improve the design of cancer vaccines or TCR engineered therapies as it could enable the more accurate selection of peptides likely to be presented on patient tumors. The gene discussed is IFNG; the disease is cancer.